Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nano-mupirocin
- Development stage
- Preclinical
- Lead developer
- Revium RX
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Parenteral
01
Overview
Nano-mupirocin is a PEGylated nano-liposomal formulation of the antibiotic mupirocin, designed to enable systemic (parenteral) administration for the treatment of deep and invasive infections caused by multidrug-resistant bacteria. Mupirocin itself is an RNA synthetase inhibitor antibacterial that acts by reversibly and specifically binding to bacterial isoleucyl-transfer RNA (tRNA) synthetase, thereby inhibiting bacterial protein synthesis. Traditionally, mupirocin has been limited to topical use due to rapid inactivation in blood; however, encapsulation in nanoliposomes protects it from degradation and allows for higher plasma levels and longer half-life after injection. Nano-mupirocin has demonstrated efficacy in animal models against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium, cephalosporin-resistant Neisseria gonorrhoeae, as well as infections such as necrotizing fasciitis, osteomyelitis, pneumonia, and endocarditis. The liposomal delivery system also facilitates uptake by macrophages for intracellular killing of bacteria[4][5][6][8].
- Other names
- nano-mupirocin
02
Targets
IleRS (Isoleucyl-tRNA synthetase)
Beyond the preview
Go deeper on nano-mupirocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nano-mupirocin.